N/A
Manufactured by Fresenius Kabi USA, LLC
16,267 FDA adverse event reports analyzed
Last updated: 2026-04-14
BLEOMYCIN SULFATE is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Fresenius Kabi USA, LLC. The most commonly reported adverse reactions for BLEOMYCIN SULFATE include FEBRILE NEUTROPENIA, OFF LABEL USE, NEUTROPENIA, DRUG INEFFECTIVE, PYREXIA. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for BLEOMYCIN SULFATE.
Out of 10,015 classified reports for BLEOMYCIN SULFATE:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
This profile reflects 16,267 FDA FAERS reports that mention BLEOMYCIN SULFATE. Reporting is voluntary and does not prove that the drug caused any listed event.
Frequently reported terms in FAERS include FEBRILE NEUTROPENIA, OFF LABEL USE, NEUTROPENIA, DRUG INEFFECTIVE, PYREXIA, PULMONARY TOXICITY. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.
Labeling and FAERS entries often list Fresenius Kabi USA, LLC in connection with BLEOMYCIN SULFATE. Always verify the specific product and NDC with your pharmacist.